The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Novavax COVID Vaccine to Be Adapted to JN.1 Strain: Takeda
Takeda Pharmaceutical said on June 6 that a two-dose vial version of its COVID-19 vaccine Nuvaxovid, licensed by Novavax, will be supplied as a shot adapted to the JN.1 strain of the novel coronavirus in Japan. Takeda filed the two-dose…
To read the full story
Related Article
- Japan Panel OKs 5 COVID Vaccines for NIP Use from October
September 20, 2024
- JN.1-Targeting Nuvaxovid Approved in Japan: Takeda
September 6, 2024
- Japan Expects COVID Vaccine Supply of 32 Million Doses from 5 Makers in 2024-25
September 3, 2024
- Japan Panel OKs BMS ROS1 Inhibitor, Janssen Bispecific, JN.1-Targeted Nuvaxovid
September 2, 2024
- BMS’ ROS1 Inhibitor, Janssen’s Bispecific Up for Review on Aug. 30
August 20, 2024
- Japan Selects JN.1 for COVID-19 Vaccine Formula in 2024-2025 Season
May 30, 2024
- Takeda Files 2-Dose Vial Version of Novavax COVID Vaccine
April 15, 2024
- Japan Ends Supply of Takeda/Novavax’s COVID Jab, 7.14 Million Doses Discarded
December 26, 2023
BUSINESS
- Sanofi Bets on Immunotherapy to Delay Onset of Type 1 Diabetes
December 19, 2025
- Japan’s 1st Eylea Biosimilar to Reach Market on January 7
December 19, 2025
- Padcev-Keytruda Pair Makes Mark in Cisplatin-Eligible MIBC: Astellas
December 19, 2025
- Daiichi Sets February Launch for Japan’s 1st OTC Morning-After Pill
December 19, 2025
- Takeda’s TYK2 Inhibitor Scores PIII Win in Psoriasis Trials, Tops Otezla on Key Metrics
December 19, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…